Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Public comment period · §2

Draft supplier evaluation rubric — submissions

The 10 submissions received, published in full with declared interests and secretariat responses.

Document identifier
CEI-CP-002/2
Series
Public comment period
Version
1.0
Published
22 Oct 2023
Last reviewed
22 Oct 2023
Next review
22 Oct 2024
Identifier
10.71829/cei.cp.2
Certainty
Not rated
Cycle
2023 Q3
Window
06 Aug 2023 – 20 Sep 2023
Status
Closed
Submissions
10

§2Submissions and responses

10 submissions were received. Each is published in full below with its declared interest, the secretariat response and the disposition. The Institute publishes submissions it did not accept in the same form as those it did.

Dr Vasilisa Immelmann, PharmD, PhD Health-technology assessment agency · submitting on regulatory science
DRAFT-SUPPLIER-RUB/001 received 07 Aug 2023

Two criteria can be satisfied without changing anything a supplier does

The respondent notes that supplier evaluation rubric produces a number that will be sorted, and submits with that in view.

The respondent identifies two criteria that are satisfied by publishing a document rather than by performing an activity, and states that both would be met by a supplier that changed only its website.

The respondent proposes that each criterion be tied to evidence of the underlying activity.

Declared interest. Holds a personal shareholding, below the Institute's materiality threshold, in a diversified fund with pharmaceutical sector exposure. No direct holding in any named company.
Secretariat responseAccepted26 Sep 2023

The secretariat accepts this submission. A criterion satisfied by a publication measures publication.

Both criteria are restated so that they are satisfied only by a document evidencing the underlying activity, such as a dated determination or a signed release record, and the rubric now states for every criterion what evidence satisfies it.

Georgiana Zimmerthal, MSc (Epidemiology) Health-technology assessment agency · submitting on public health
DRAFT-SUPPLIER-RUB/002 received 07 Aug 2023

Declared interests should appear on the document rather than on a separate page

The respondent submits on supplier evaluation rubric. A supplier score will be read as a statement about product whatever the accompanying text says, and the design of the instrument has to take that as given.

The draft links to a central conflicts register. The respondent argues that a reader assessing whether to rely on a particular document should not have to leave it to find out who assessed it and what they declared.

The respondent proposes that the interests of every named contributor to a document be printed on that document.

The respondent notes submission 001 above and does not repeat the ground it covers.

Declared interest. Holds a personal shareholding, below the Institute's materiality threshold, in a diversified fund with pharmaceutical sector exposure. No direct holding in any named company.
Secretariat responseNoted, no amendment22 Oct 2023

The secretariat notes this submission and records that the draft already provides for it, which the respondent could reasonably have missed because the provision sits in an appendix.

Every document carries the declared interests of its named contributors in its front matter, and the central register exists so that a reader can see a person across all documents rather than one at a time. No amendment arises; the provision has been moved from the appendix into the body of the methodology document so that it is findable.

Dr Quentin Zimmerthal, PhD (Chemistry), CChem Independent analytical consultancy · submitting on analytical chemistry
DRAFT-SUPPLIER-RUB/003 received 11 Aug 2023

Two anchors on the same criterion can both describe the same supplier

The draft of supplier evaluation rubric was read by a respondent whose interest is in what a supplier could do to raise a score without changing anything else.

On the certificate criterion, a supplier reporting purity with a method but no content matches one anchor, and a supplier reporting purity with content but no method matches another. A supplier reporting neither matches both descriptions equally poorly.

The respondent proposes that anchors be rewritten as a checklist of present fields rather than as prose descriptions.

Declared interest. Holds a patent relating to a delivery technology referenced in the draft.
Secretariat responseAccepted in part13 Oct 2023

The secretariat accepts the diagnosis and adopts a narrower remedy.

The anchors are retained in prose, because a checklist would score a certificate carrying every field badly filled as though it were complete. Each anchor now names the fields that must be present for it to be reached, so that two anchors cannot describe one certificate.

Dr Fitzwilliam Danquah-Öberg, PhD (Chemistry), CChem Independent analytical consultant · submitting on analytical chemistry
DRAFT-SUPPLIER-RUB/004 received 14 Aug 2023

Documentary practice is weighted equally with analytical evidence

This submission addresses supplier evaluation rubric from the standpoint of a reader who will see a score and not the rubric behind it.

The respondent states that a supplier can score well on documentation while releasing material on certificates generated by a third party it does not name, and that the two dimensions should not carry equal weight.

The respondent proposes that analytical evidence carry twice the weight of documentary practice.

Declared interest. Has received consultancy fees from a supplier named in the Institute's supplier assessment set within the preceding two years.
Secretariat responseAccepted in part12 Oct 2023

The secretariat accepts this submission in part. The weighting is adjusted, though not to the ratio proposed, and a gate is added that the weighting alone would not achieve.

Analytical evidence now carries greater weight than documentary practice, and a supplier that does not identify the laboratory performing its determinations cannot reach the upper band regardless of its total score.

Dr Eamon Immelmann, PhD (Chemistry), CChem Independent analytical consultancy · submitting on analytical chemistry
DRAFT-SUPPLIER-RUB/005 received 20 Aug 2023

Whether a purchaser can obtain the record behind a figure is not scored

This is a submission on supplier evaluation rubric, made from an analytical standpoint.

A certificate reporting a purity figure is worth more where the chromatogram behind it can be obtained on request and less where it cannot. The rubric scores the certificate and not the availability of the record.

The respondent proposes that availability of the underlying record on written request be scored within the transparency criterion.

Declared interest. Holds a patent relating to a delivery technology referenced in the draft.
Secretariat responseAccepted20 Oct 2023

The secretariat accepts this submission.

Availability of the underlying record on written request is now an anchor within the transparency criterion, tested by request during each assessment cycle and recorded in the correspondence log.

Stellan Cholmondeley-Ade, MSc (Clinical Pharmacy) Regional hospital pharmacy department · submitting on medicines information
DRAFT-SUPPLIER-RUB/006 received 26 Aug 2023

Scores from different rubric versions are presented together

This submission concerns the draft of supplier evaluation rubric. The respondent works in a dispensing setting and sees how documents of this kind are used in practice.

The respondent states that dossiers assessed under an earlier version of the rubric appear in the same table as those assessed under the current one, and that the scores are not comparable.

The respondent proposes that the rubric version be carried with every score.

The respondent supports submission 005 so far as it goes and adds the matter set out here.

Declared interest. Has received travel support to attend a scientific meeting from a manufacturer of a compound named in the draft.
Secretariat responseAccepted19 Oct 2023

The secretariat accepts this submission. A score without its rubric version is not a measurement.

Every score now carries the rubric version and the assessment date, the comparison table displays only scores made under the current version, and dossiers not yet reassessed are shown as awaiting reassessment rather than with a stale score.

Dr Yaa Kettlewell, PhD (Biostatistics) Independent evidence-synthesis consultancy · submitting on biostatistics
DRAFT-SUPPLIER-RUB/007 received 29 Aug 2023

Point estimates are given without an interval

Having read the draft of supplier evaluation rubric, the respondent puts one point to the secretariat.

Several estimates in the draft appear as single figures. The respondent states that a point estimate without an interval invites a precision the underlying data do not support, and that the effect is worst where the estimate is drawn from a small contributing set.

The respondent proposes that no point estimate appear anywhere in the document set without its interval, including in summary tables and in the abstract.

Declared interest. No financial or non-financial interest to declare in relation to the subject of this consultation.
Secretariat responseAccepted in part05 Oct 2023

The secretariat accepts this submission in part. Intervals are added wherever the source reports one. The proposal is declined for figures the source published without an interval, because the Institute will not compute an interval a source did not report.

Every estimate now carries its interval where the source reported one, and where it did not, the estimate is annotated as reported without an interval rather than left to appear as a precise figure.

Dr Zebedee Zaleski-Mbeki, MD, FRCPath Hospital microbiology and endotoxin testing service · submitting on clinical biochemistry
DRAFT-SUPPLIER-RUB/008 received 06 Sep 2023

An accreditation claim is scored without being verified

The respondent’s comment on supplier evaluation rubric arises from having assessed supplier documentation professionally.

The respondent states that the rubric awards credit for a claimed accreditation, and that accreditation claims in this sector are frequently unverifiable or refer to a scope that does not cover the determinations reported.

The respondent proposes that credit be awarded only where the accreditation and its scope are verified against the accrediting body's own register.

Declared interest. Has received consultancy fees from a supplier named in the Institute's supplier assessment set within the preceding two years.
Secretariat responseAccepted19 Oct 2023

The secretariat accepts this submission. An unverified claim scored as though verified imports the claim into the Institute's own assessment.

Credit for accreditation is now awarded only where the Institute has verified the accreditation and its scope against the accrediting body's register, the verification date is recorded in the dossier, and an unverifiable claim is recorded as claimed and unverified with no credit.

Dr Oisín Rautavaara, PhD (Pharmacoepidemiology) Public-sector clinical trials unit · submitting on biostatistics
DRAFT-SUPPLIER-RUB/009 received 12 Sep 2023

Scores are reported to a precision the underlying judgements do not support

The respondent read supplier evaluation rubric in draft and has confined this submission to a single criterion.

The respondent states that scores are reported to one decimal place while the underlying criteria are judged on coarse ordinal scales, and that the precision is spurious.

The respondent proposes that scores be reported as whole numbers.

Declared interest. Has previously served as an investigator on a trial included in the evidence base under consultation. Received no personal payment; institutional payment was made to the trial site.
Secretariat responseAccepted in part05 Oct 2023

The secretariat accepts this submission in part. Reported precision is reduced. Scores are not rounded to whole numbers, because the resulting ties would themselves be read as findings of equivalence.

Scores are now reported to the precision the criteria support, the criterion-level judgements are published alongside the total so that the derivation can be checked, and the dossier states that a difference smaller than the reported precision is not a difference.

Dr Frideswide Nordhagen, BPharm, PhD University department of pharmacy practice · submitting on pharmacy practice
DRAFT-SUPPLIER-RUB/010 received 19 Sep 2023

A high score invites a purchasing decision the rubric cannot support

The respondent has read supplier evaluation rubric in draft and makes one submission.

The rubric assesses documentation. A reader comparing two scores is making a purchasing decision, and the disclaimer accompanying the score does not prevent it because the disclaimer is read once and the score is read every time.

The respondent proposes that the scope of the score be printed in the same line as the score wherever it appears, rather than in a notice above the table.

Declared interest. Holds a personal shareholding, below the Institute's materiality threshold, in a diversified fund with pharmaceutical sector exposure. No direct holding in any named company.
Secretariat responseAccepted13 Oct 2023

The secretariat accepts this submission.

The scope of the score is now printed in the same row as the score on every surface that carries it, in the same weight, rather than in a separate notice.

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

  1. International Organization for Standardization. ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories. ISO/IEC Standard 2017;3rd edition. identifier not held by the Institute

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.